BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/2/2015 12:20:00 PM | Browse: 889 | Download: 1116
Publication Name World Journal of Hepatology
Manuscript ID 11345
Country Japan
Received
2014-05-16 21:22
Peer-Review Started
2014-05-18 23:24
To Make the First Decision
2014-06-27 12:02
Return for Revision
2014-07-04 12:19
Revised
2014-07-16 23:28
Second Decision
2014-08-31 16:59
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2014-08-31 17:16
Articles in Press
2014-08-31 17:17
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2014-09-30 16:17
Publish the Manuscript Online
2014-10-19 20:39
ISSN 1948-5182 (online)
Open Access
Copyright
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Retrospective Study
Article Title Skin toxicity predicts efficacy to sorafenib in patients with advanced hepatocellular carcinoma
Manuscript Source Unsolicited Manuscript
All Author List Masako Shomura, Tatehiro Kagawa, Koichi Shiraishi, Shunji Hirose, Yoshitaka Arase, Jun Koizumi and Tetsuya Mine
Funding Agency and Grant Number
Funding Agency Grant Number
Japan Society for the Promotion of Science (JSPS) KAKENHI Grant-in-Aid for Young Scientists (B) 21792240
Corresponding Author Masako Shomura, RN, PhD, Associate Professor, Department of Nursing, Tokai University School of Health Sciences, 143 Shimokasuya, Isehara, Kanagawa 2591193, Japan. rocky36j@is.icc.u-tokai.ac.jp
Key Words Hepatocellular carcinoma; Molecular targeted therapy; Drug toxicity; Surrogate marker; Nursing intervention
Core Tip Sorafenib therapy for advanced hepatocellular carcinoma (HCC) often causes adverse events (AEs), subsequently leading to dose reduction or discontinuation. Conversely, few studies have associated serious AEs with a favorable response to sorafenib. We aimed to elucidate the relationship between AEs occurrence, therapeutic efficacy, and the impact of nursing intervention on adherence to therapy. We observed that skin toxicity was associated with favorable outcomes in sorafenib therapy for advanced HCC. Furthermore nursing intervention contributed to better adherence, which may improve the efficacy of sorafenib therapy.
Publish Date 2014-10-19 20:39
Citation Shomura M, Kagawa T, Shiraishi K, Hirose S, Arase Y, Koizumi J, Mine T. Skin toxicity predicts efficacy to sorafenib in patients with advanced hepatocellular carcinoma. World J Hepatol 2014; 6(9): 670-676
URL http://www.wjgnet.com/1948-5182/full/v6/i9/670.htm
DOI http://dx.doi.org/10.4254/wjh.v6.i9.670
Full Article (PDF) WJH-6-670.pdf
Full Article (Word) WJH-6-670.doc
Manuscript File 11345-Review.docx
Answering Reviewers 11345-Answering reviewers.pdf
Copyright License Agreement 11345-Copyright assignment.pdf
Institutional Review Board Approval Form or Document Ethics_Committee_20140516205039.pdf
Non-Native Speakers of English Editing Certificate 11345-Language certificate.pdf
Peer-review Report 11345-Peer review(s).pdf
Scientific Misconduct Check 11345-CrossCheck.jpg
Scientific Editor Work List 11345-Scientific editor work list.pdf